Drug-eluting stents versus bare-metal stents with a single month of dual antiplatelet therapy: a trial sequential analysis

This is a preview of subscription content, log in to check access.

Fig. 1


  1. 1.

    Capodanno D, Alfonso F, Levine G et al (2018) ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol 72:2915–2931

    Article  PubMed  Google Scholar 

  2. 2.

    Valina C, Merz S, Löffelhardt N et al (2018) Risk of discontinuation of clopidogrel after 1 month following bare-metal stents: a propensity-score adjusted comparison with continued administration of clopidogrel after drug-eluting stents. J Thromb Thrombolysis 45:432–439

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Shah R, Rao SV, Latham SB, Kandzari DE (2018) Efficacy and safety of drug-eluting stents optimized for biocompatibility vs bare-metal stents with a single month of dual antiplatelet therapy: a meta-analysis. JAMA Cardiol 3:1050–1059

    Article  PubMed  Google Scholar 

  4. 4.

    Thorlund K, Devereaux PJ, Wetterslev J et al (2009) Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol 38:276–286

    Article  PubMed  Google Scholar 

  5. 5.

    Brok J, Thorlund K, Gluud C, Wetterslev J (2008) Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 61:763–769

    Article  PubMed  Google Scholar 

  6. 6.

    Kirtane A (2018) Is there any current role for bare-metal coronary stents? JAMA Cardiol 3:1059

    Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Deepak L. Bhatt.

Ethics declarations

Conflicts of interest

DLB discloses the following relationships—Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, PLx Pharma, Takeda. The remaining authors report no relationships that could be construed as a conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kheiri, B., Bachuwa, G. & Bhatt, D.L. Drug-eluting stents versus bare-metal stents with a single month of dual antiplatelet therapy: a trial sequential analysis. J Thromb Thrombolysis 48, 11–13 (2019). https://doi.org/10.1007/s11239-019-01861-6

Download citation